A Phase 2 interventional study of Saroglitazar Magnesium 2mg and Saroglitazar Magnesium 4mg in Non Alcoholic Steatohepatitis, sponsored by Zydus Therapeutics Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 387th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 277th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 62 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zydus Therapeutics Inc., one of the names counted as Zydus Lifesciences Limited. Under that name alone:
Zydus Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Zydus Lifesciences Limited has 7 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of Saroglitazar Magnesium 2 mg and 4 mg in patients with NASH. This study will be initiated after obtaining the approvals of Institutional Ethics Committee/Institutional Review Board (IEC/IRB) and the local regulatory authority.
Patients clinically suspected of NASH will be invited for a screening programme for inclusion in the study. Patients will be screened according to the inclusion and exclusion criteria. Clinical evaluation will be conducted for baseline characteristics and anthropometry measurements such as body weight and height.
After clinical evaluations, all baseline safety and efficacy parameters will be recorded as per Visit Schedule. All laboratory collections will be performed following overnight fasting (at least 8 hrs).
Following confirmation of all clinical and laboratory inclusion and exclusion criteria, patients will continue into the screening period. During the screening period liver biopsy will be performed. However, if a biopsy was performed within 6 months the slides and biopsy material, or block, must be made available for baseline documentation. Such Patients, whose historical biopsy report is available, should not use medication suspected of having an effect on NASH from the 3 months prior to the screening.
Liver biopsy will be performed to confirm the diagnosis of NASH and record a baseline Non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS). The histological evidence of NASH is defined as NAS ≥ 4 with a minimum score of 1 for all of its three components [steatosis, hepatocyte ballooning and lobular inflammation].
Following confirmation of inclusion/exclusion criteria and upon histological confirmation of NASH by liver biopsy, patients will be enrolled into the study.
Eligible patients will be randomly assigned to receive Saroglitazar Magnesium 2 mg or 4 mg or placebo in a 2:2:1 ratio for 24 weeks.
Upon completion of 24 weeks of treatment, liver biopsy will be performed and the NAFLD Activity Score recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with type 2 diabetes mellitus may be included if they fulfil the following criteria;
Exclusion Criteria:
Any of the following laboratory values at screening:
Unstable cardiovascular disease, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast for 24 weeks.
Drug: Saroglitazar Magnesium 2mg
Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.
Drug: Saroglitazar Magnesium 4mg
Placebo tablet orally once daily in the morning before breakfast for 24 weeks.
Drug: Placebos
Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.
Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.
Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
NAS Score (Nonalcoholic Fatty Liver Disease [NAFLD] Activity Score)
The primary endpoint is to assess the changes in NAFLD Activity Score (NAS) at week 24 from baseline and with no worsening of fibrosis in NASH patients. NAFLD Activity Score Steatosis \<5% - 0 5% -33% - 1 \>33% -66% - 2 \>66% - 3 Lobular Inflammation No foci - 0 \<2 foci per 200 X field -1 2-4 foci per 200 X field - 2 \>4 foci per 200 X field - 3 Ballooning None - 0 Few balloon cells -1 Many cells/prominent ballooning - 2 Final NAFLD Activity Score = Steatosis Score + Lobular Inflammation Score + Ballooning Score Minimum score for NAS is 0 Maximum score for NAS is 8 Higher score represents the worse disease activity
Time frame: Baseline to Week 24
To Evaluate the Percentage of Responders in the Treatment Groups.
Responder is defined as a decrease from baseline of at least 2 points spread across at least 2 of the NAS components \[steatosis, hepatocyte ballooning, and lobular inflammation\] with no worsening of fibrosis.
Time frame: Baseline to Week 24
Percentage of Responders Defined by the Disappearance of Steatohepatitis.
Percentage of responders defined by the disappearance of steatohepatitis
Time frame: Baseline to Week 24
Changes in the Stage of Steatosis, Lobular Inflammation and Ballooning.
Changes in the stage of steatosis, lobular inflammation and ballooning by evaluating the NAS Score (Nonalcoholic fatty liver disease Activity Score) Steatosis \<5% - 0 5% -33% - 1 \>33% -66% - 2 \>66% - 3 Lobular Inflammation No foci - 0 \<2 foci per 200 X field -1 2-4 foci per 200 X field - 2 \>4 foci per 200 X field - 3 Ballooning None - 0 Few balloon cells -1 Many cells/prominent ballooning - 2 Higher score represents the worse disease activity
Time frame: Baseline to Week 24
Changes in the Stage of Fibrosis.
Changes in the stage of fibrosis by evaluating the Fibrosis stages Fibrosis Score Definition None - 0 Perisinusoidal or periportal - 1 Mild, zone 3, perisinusoidal - 1A Moderate, zone3, perisinusoidal -1B Portal/periportal -1C Perisinusoidal and portal/periportal - 2 Bridging fibrosis - 3 Cirrhosis - 4 Higher score represents the worse disease activity
Time frame: Baseline to Week 24
Changes in the Liver Function Tests; (Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], Alkaline Phosphatases [ALP], and Gamma-glutamyl Transferase [GGT]).
Liver function tests include ALT, AST, ALP, GGT
Time frame: Baseline to Week 24
Changes in the Liver Function Tests; Albumin and Total Protein
Changes in albumin and total protein
Time frame: Baseline to Week 24
Changes in the Liver Function Tests; Direct Bilirubin
Change in direct bilirubin
Time frame: Baseline to Week 24
Changes in the Lipid Profile.
Evaluation of Lipid profile parameters
Time frame: Baseline to Week 24
Number of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium 2 mg and 4 mg
Number of Participants with Adverse Events.
Time frame: Baseline to Week 24
Changes in the Glycemic Control and Insulin Resistance; Fasting Plasma Glucose
Evaluation of Fasting Plasma Glucose
Time frame: Baseline to Week 24
Changes in the Glycemic Control and Insulin Resistance; Hemoglobin A1c
Evaluation of Hemoglobin A1c
Time frame: Baseline to Week 24
Changes in the Glycemic Control and Insulin Resistance; Insulin
Evaluation of Insulin
Time frame: Baseline to Week 24
Changes in the Glycemic Control and Insulin Resistance: C-peptide
Evaluation of C-peptide
Time frame: Baseline to Week 24
Changes in the Glycemic Control and Insulin Resistance: Homeostasis Model Assessment of Beta Cell Function (HOMA -β)
Evaluation of HOMA of Beta Cell Function Homeostasis model assessment of beta cell function measures as following; HOMA -β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}. HOMA-B provides a quantitative estimate of beta-cell function. A lower HOMA-B value indicates reduced beta-cell function, which can be a sign of progressing towards or already having type 2 diabetes. Conversely, a higher HOMA-B value suggests better beta-cell functionality.
Time frame: Baseline to Week 24
Changes in the Glycemic Control and Insulin Resistance: HOMA of Insulin Resistance
Evaluation of HOMA of Insulin Resistance Insulin Resistance Index measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.
Time frame: Baseline to Week 24
Changes in the Glycemic Control and Insulin Resistance: Total Adiponectin
Evaluation of Total Adiponectin
Time frame: Baseline to Week 24
| Milestone | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Started | 6 | 7 | 3 |
| Completed | 6 | 7 | 3 |
| Not completed | 0 | 0 | 0 |
The primary endpoint is to assess the changes in NAFLD Activity Score (NAS) at week 24 from baseline and with no worsening of fibrosis in NASH patients. NAFLD Activity Score Steatosis \<5% - 0 5% -33% - 1 \>33% -66% - 2 \>66% - 3 Lobular Inflammation No foci - 0 \<2 foci per 200 X field -1 2-4 foci per 200 X field - 2 \>4 foci per 200 X field - 3 Ballooning None - 0 Few balloon cells -1 Many cells/prominent ballooning - 2 Final NAFLD Activity Score = Steatosis Score + Lobular Inflammation Score + Ballooning Score Minimum score for NAS is 0 Maximum score for NAS is 8 Higher score represents the worse disease activity
| units on a scale | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| NAS Score (Nonalcoholic Fatty Liver Disease [NAFLD] Activity Score) | -1.50 ± 0.84 | -1.86 ± 1.57 | -1.33 ± 0.58 |
Responder is defined as a decrease from baseline of at least 2 points spread across at least 2 of the NAS components \[steatosis, hepatocyte ballooning, and lobular inflammation\] with no worsening of fibrosis.
| Participants | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| To Evaluate the Percentage of Responders in the Treatment Groups. | 4 | 3 | 1 |
Percentage of responders defined by the disappearance of steatohepatitis
| Participants | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Percentage of Responders Defined by the Disappearance of Steatohepatitis. | 5 | 6 | 0 |
Changes in the stage of steatosis, lobular inflammation and ballooning by evaluating the NAS Score (Nonalcoholic fatty liver disease Activity Score) Steatosis \<5% - 0 5% -33% - 1 \>33% -66% - 2 \>66% - 3 Lobular Inflammation No foci - 0 \<2 foci per 200 X field -1 2-4 foci per 200 X field - 2 \>4 foci per 200 X field - 3 Ballooning None - 0 Few balloon cells -1 Many cells/prominent ballooning - 2 Higher score represents the worse disease activity
| units on a scale | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Changes in the stage of steatosis | -0.50 ± 0.55 | -0.71 ± 0.76 | -0.33 ± 0.58 |
| Changes in the stage of lobular inflammation | -0.17 ± 0.41 | -0.29 ± 0.49 | -0.67 ± 0.58 |
| Changes in the stage of ballooning | -0.83 ± 0.41 | -0.86 ± 0.90 | -0.33 ± 0.58 |
Changes in the stage of fibrosis by evaluating the Fibrosis stages Fibrosis Score Definition None - 0 Perisinusoidal or periportal - 1 Mild, zone 3, perisinusoidal - 1A Moderate, zone3, perisinusoidal -1B Portal/periportal -1C Perisinusoidal and portal/periportal - 2 Bridging fibrosis - 3 Cirrhosis - 4 Higher score represents the worse disease activity
| units on a scale | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Changes in the Stage of Fibrosis. | -0.50 ± 0.84 | -0.43 ± 0.79 | 0.33 ± 0.58 |
Liver function tests include ALT, AST, ALP, GGT
| U/L | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Change in ALT | -22.83 ± 14.29 | -29.57 ± 26.76 | -14.67 ± 48.95 |
| Change in AST | -10.33 ± 5.32 | -16.29 ± 11.63 | -19.33 ± 47.44 |
| Change in ALP | -24.00 ± 9.92 | -23.86 ± 15.18 | 3.67 ± 5.13 |
| Change in GGT | -23.83 ± 18.55 | -28.43 ± 33.30 | -1.67 ± 19.50 |
Changes in albumin and total protein
| g/dL | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Change in albumin | -0.05 ± 0.22 | -0.04 ± 0.17 | 0.13 ± 0.12 |
| Change in total protein | -0.08 ± 0.40 | 0.09 ± 0.41 | 0.27 ± 0.06 |
Change in direct bilirubin
| mg/dL | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Changes in the Liver Function Tests; Direct Bilirubin | -0.01 ± 0.03 | -0.01 ± 0.02 | -0.00 ± 0.02 |
Evaluation of Lipid profile parameters
| mg/dL | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Change in Triglyceride | -40.33 ± 38.37 | -16.71 ± 44.31 | -6.00 ± 34.04 |
| Change in Total Cholesterol | 11.17 ± 40.45 | -16.00 ± 31.12 | -0.33 ± 9.02 |
| Change in Small dense LDL | 1.27 ± 15.99 | -9.29 ± 11.85 | 5.87 ± 6.66 |
| Change in High-density Lipoprotein | 6.33 ± 14.85 | -0.14 ± 8.47 | 7.00 ± 4.36 |
| Change in Low-density lipoprotein | 13.00 ± 34.89 | -12.57 ± 28.11 | -6.00 ± 5.29 |
| Change in Very low-density lipoprotein | -8.17 ± 7.41 | -3.29 ± 8.88 | -1.33 ± 6.51 |
| Change in non-HDL Cholesterol | 4.83 ± 33.68 | -15.86 ± 29.23 | -7.33 ± 9.29 |
| Change in Apo lipoprotein A1 | 10.50 ± 36.74 | -14.29 ± 26.98 | 7.33 ± 2.08 |
| Change in Apo lipoprotein B | 1.00 ± 26.53 | -14.71 ± 21.04 | -1.33 ± 4.62 |
Number of Participants with Adverse Events.
| Participants | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Number of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium 2 mg and 4 mg | 3 | 5 | 2 |
Evaluation of Fasting Plasma Glucose
| mg/dL | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Changes in the Glycemic Control and Insulin Resistance; Fasting Plasma Glucose | 2.67 ± 19.18 | -0.86 ± 41.10 | 7.67 ± 12.50 |
Evaluation of Hemoglobin A1c
| percentage of HbA1c | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Changes in the Glycemic Control and Insulin Resistance; Hemoglobin A1c | -0.52 ± 0.65 | -0.09 ± 0.28 | 0.03 ± 0.35 |
Evaluation of Insulin
| μIU/mL | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Changes in the Glycemic Control and Insulin Resistance; Insulin | -1.05 ± 20.05 | 6.74 ± 15.34 | 8.13 ± 12.32 |
Evaluation of C-peptide
| ng/mL | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Changes in the Glycemic Control and Insulin Resistance: C-peptide | -1.09 ± 2.26 | 0.08 ± 1.41 | 0.27 ± 0.95 |
Evaluation of HOMA of Beta Cell Function Homeostasis model assessment of beta cell function measures as following; HOMA -β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}. HOMA-B provides a quantitative estimate of beta-cell function. A lower HOMA-B value indicates reduced beta-cell function, which can be a sign of progressing towards or already having type 2 diabetes. Conversely, a higher HOMA-B value suggests better beta-cell functionality.
| percentage of HOMA of Beta Cell Function | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Changes in the Glycemic Control and Insulin Resistance: Homeostasis Model Assessment of Beta Cell Function (HOMA -β) | -34.35 ± 84.41 | 14.49 ± 358.04 | 30.10 ± 46.15 |
Evaluation of HOMA of Insulin Resistance Insulin Resistance Index measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.
| percentage of HOMA of Insulin Resistance | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Changes in the Glycemic Control and Insulin Resistance: HOMA of Insulin Resistance | 0.45 ± 8.30 | 2.73 ± 5.77 | 2.34 ± 4.18 |
Evaluation of Total Adiponectin
| μg/mL | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Changes in the Glycemic Control and Insulin Resistance: Total Adiponectin | 1.84 ± 2.17 | 0.68 ± 3.28 | 1.50 ± 4.02 |
Collected over 24 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saroglitazar Magnesium 2 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Saroglitazar Magnesium 4 mg | 0/7 (0%) | 2/7 (28.6%) | 5/7 (71.4%) |
| Placebo | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Event | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| AppendicitisInfections and infestations | 0/6 | 1/7 | 0/3 |
| BronchitisInfections and infestations | 0/6 | 1/7 | 0/3 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/6 | 1/7 | 0/3 |
| Event | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|
| Fungal infectionInfections and infestations | 0/6 | 0/7 | 1/3 |
| Lower respiratory tract infectionInfections and infestations | 0/6 | 0/7 | 1/3 |
| DiarrheaGastrointestinal disorders | 1/6 | 0/7 | 1/3 |
| FlatulenceGastrointestinal disorders | 0/6 | 0/7 | 1/3 |
| AmnesiaNervous system disorders | 0/6 | 0/7 | 1/3 |
| FatigueGeneral disorders | 1/6 | 0/7 | 1/3 |
| Rash pruriticSkin and subcutaneous tissue disorders | 0/6 | 0/7 | 1/3 |
| InfluenzaInfections and infestations | 0/6 | 2/7 | 0/3 |
| Tooth abscessInfections and infestations | 1/6 | 0/7 | 0/3 |
| Urinary tract infectionInfections and infestations | 1/6 | 0/7 | 0/3 |
| Age, Continuous(Years) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 48.67 ± 9.91 | 50.57 ± 16.48 | 63.33 ± 8.08 | 52.25 ± 13.46 |
| Sex: Female, Male(Participants) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 5 | 6 | 3 | 14 |
| Male | 1 | 1 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 1 | 5 |
| Not Hispanic or Latino | 5 | 3 | 2 | 10 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 2 |
| White | 5 | 7 | 2 | 14 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 6 | 7 | 3 | 16 |
| Body Mass Index(kg/m^2) | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 37.32 ± 5.85 | 37.89 ± 8.27 | 37.67 ± 12.76 | 37.63 ± 7.78 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in Mar 2020, 9 months.
Results were first posted in Oct 2024, 4 years 6 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 9 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Saroglitazar
Non-alcoholic Fatty Liver Disease →